Brandenburg, Vincent M.
Sinha, Smeeta
Torregrosa, Jose-Vicente
Garg, Rekha
Miller, Stephan
Canals, Ana-Zeralda
Bahr, Daun
Joubert, Pieter H.
Salcedo, Carolina
Carroll, Kevin J.
Gold, Alex
Perelló, Joan
Funding for this research was provided by:
Laboratoris Sanifit
Article History
Received: 30 March 2019
Accepted: 13 July 2019
First Online: 10 August 2019
Compliance with ethical standards
:
: VB is a consultant to Pharmacosmos, Vifor, and FMC, received lecture fees from Amgen, Pfizer, Bayer, Pharmacosmos, Vifor, FMC, Servier, Novartis, Daiichi-Sankyo, and Cardiobridge, received a grant for the European Calciphylaxis Network EuCalNet from Amgen, and received grants from Pfizer, Bayer, Sanifit, Pharmacosmos, Vifor, FMC, Servier, Novartis, Daiichi-Sankyo, and Cardiobridge. SS is a consultant to Sanifit, and received lecture fees from Vifor Fresenius, MSD, and Boehringer Ingelheim. JT has no conflicts to disclose. KJC and PJ, are consultants to Sanifit. RG, SM and AG are employees and shareholders of Sanifit Therapeutics. AZC is an employee and shareholders of Sanifit and has a patent pending related to SNF472. CS is an employee of Sanifit and has patents related to SNF472. JP is an employee and shareholder of Sanifit, and has patents owned or controlled by Sanifit.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Patients gave written informed consent to participate.